

Index

A

- Adult-onset still's disease (AOSD)
 - autoinflammatory syndromes, 23
 - etiology infections, 25
 - juvenile rheumatoid arthritis (JRA), 23
 - nonsteroidal anti-inflammatory drugs (NSAIDs), 25
 - serum ferritin level, 26
 - Alzheimer's dementia, 470
 - American College of Rheumatology (ACR), 1, 131, 132, 146, 163, 229, 253, 373, 430
 - Amyloidosis
 - Alzheimer's dementia, 470
 - apple-green birefringence, 467
 - cardiac involvement, 468
 - diagnostic and prognostic feature, 466
 - Familial Mediterranean fever (FMF), 469
 - fat pad aspiration, 467
 - macroglossia, 468
 - monoclonal gammopathies, 469
 - nomenclature and tissue study, 466
 - periorbital purpura, 468
 - treatment approaches, 469
 - ANCA-associated vasculitis (AAV)
 - antithyroid medications, 264
 - arthritis and arthralgias, 261
 - chemosis, 254
 - epidemiology, 247
 - kidneys
 - persistent hematuria, 259
 - renal transplantation, 260, 261
 - nasal crusting, 249
 - nose irrigating device, 250
 - saddle nose, 247–249
 - subglottic stenosis, 250–253
 - treatment and course, 264–267
 - vasculitic skin lesion, 261
 - Ankylosing spondylitis (AS)
 - anti-TNF therapy, 62
 - C-reactive protein (CRP) levels, 58
 - Forestier's disease, 60
 - HLA-B27 positive, 58
 - injectable glucocorticoid preparations, 62
 - Klebsiella infections, 61
 - physiotherapy, 63
 - prognosis, 57
 - radiographic pattern, 59
 - radiological progression, 63
 - sacroiliitis, 59
 - spondyloarthritis, 57
 - syndesmophytes, 60
 - systemic inflammatory disorders, 63
 - TNF blockers, 62
 - Anterior ischemic optic neuropathy (AION)
 - arteritic-AION, 290
 - fluorescein angiogram, 304
 - vasculitic occlusion, 289
 - Antineutrophil cytoplasmic antibodies (ANCA), 18, 21, 263–264
 - Antinuclear antibody assay (ANA), 77, 80, 131–132, 197, 277, 381
 - Antiphospholipid syndrome (APS)
 - antiphospholipid antibodies (aPL)
 - immune thrombocytopenia (ITP), 176
 - transverse myelitis, 175
 - central nervous system manifestations, 174
 - cerebral vasculitis, 177
 - classification criteria, 176
 - clinical manifestations, 174
 - cutaneous manifestation (see Livedo reticularis)
 - dermatologic manifestation (see Livedo racemosa)
 - menorrhagia, 179
 - nephropathy, 176–177
 - pregnancy management, 179
 - thrombosis
 - anticoagulation, 178, 179
 - and pregnancy morbidity, 174–175
 - venous thrombosis, 178
 - Arthralgias, 134
 - Arthritogenic pathogens, 75
 - Arthrocentesis
 - bursal fluid characteristics, 439
 - coagulopathy and thrombocytopenia, 437
 - glucocorticoids injections, 437, 438
 - Rule of Twos, 437
 - synovial fluid count, 438
 - Atrophic papillae, 113
 - Autoimmune lymphoproliferative syndrome (ALPS), 164
- ## B
- Bath AS disease activity index (BASDAI), 58, 63, 64
 - B cell lymphomas, 121, 123, 125, 126
 - Behçet's syndrome, 284
 - vs. autoinflammatory disorder, 234
 - azathioprine and interferon-alpha treatment, 238
 - cardinal characteristic, 233
 - clinical manifestations, 238–239
 - colchicine treatment, 233
 - vs. connective tissue disorder, 234
 - cutaneous hyperpigmentation, 235
 - genital ulcer, scrotum, 236, 237
 - intermittent claudication, 237
 - MRI, 239
 - vs. multiple sclerosis, 239

- papulopustular lesions, 234
 parenchymal lung disease, 237
 sex differences, disease phenotype, 237
 spondyloarthropathy, 233–234
 sterile pustules, 235
 superficial thrombophlebitis, 236
 Bell's palsy, 414
 Benign joint hypermobility syndrome (BJHS), 475
 Bilateral hilar adenopathy, 414–415
 Birdshot retinochoroidopathy, 385
 Bone marrow edema syndrome, 483
 Bone scintigraphy, Paget's disease, 410
 Buerger's disease. *See* Thromboangiitis obliterans
 Bullous lupus erythematosus, 139, 140
- C**
- Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease, 3, 4
 diagnosis
 intracellular vs. extracellular crystals, 377
 metabolic causes, 377
 talc and glucocorticoids crystals, 376
 epidemiology, 377–378
 pathophysiology, 378–379
 symptoms and signs
 clinical clues, 375
 crowned dens syndrome, 373–374
 joints pain, 374
 medical and surgical procedures, 376
 meniscal cartilage of knee and fibrocartilage of wrist, 375
 monosodium urate coexistence, 376
 polyarticular inflammatory arthritis, 373
 tumoral deposits, 376
 treatment and outcomes, 379
 Cannabis arteritis, 323
 Carpal tunnel syndrome (CTS), 93, 443
 Central nervous system (CNS) disease, 120, 147
 Cerebral vein thrombosis, 161
 Cervical myelopathy, 462
 Chrysotherapy, 9
 Churg–Strauss syndrome (CSS)
 ANCA-associated vasculitis, 242
 capillaritis, 243
 CT scan, lung, 243
 cytotoxic agent treatment, 245
 histopathologic findings, 241
 leukotriene inhibitors, 242
 lung parenchyma involvement, 243
 lymphadenopathy, 242
 necrotizing and non-necrotizing vasculitis, 242
 nerve infarction, 245
 peripheral nerve and myocardium predilection, 244
 persistent asthma, 245
 phases of, 241
 rheumatoid nodules, 244
 tongue wasting, 245
 Clinical disease activity index (CDAI), 6, 7
 Cogan's syndrome
 audiograms, 330
 autoantibody profile, 329–330
 causing meningitis, 331
 eye in, 331
 hearing loss, 329
 interstitial keratitis, 330
 ocular inflammation, 330–331
 Cognitive behavioral therapy, FM, 351
- Colchicine therapy, 37, 366, 370
 Connective tissue disease syndrome, 80, 115, 133
 C-reactive protein (CRP), 58, 122, 148
 Cryoglobulinemia
 clinical manifestations, 271
 cryocrit correlation, 273
 etiologic factor, 274
 hepatitis C virus (HCV) infections, 271
 mononeuritis multiplex, 273
 plasmapheresis, 275
 pulmonary–renal syndrome, 274
 renal biopsies, 273
 renal disease, 272
 ribavirin, 274
 type II/III cryoglobulinemic vasculitis, 272
 Cutaneous systemic sclerosis, 103
 Cutaneous vasculitis, 116, 228, 280
- D**
- Dermatomyositis (DM)
 amyopathic DM, 195
 cutaneous finding, 194
 muscle disease, diagnosis, 194
 periungual erythema, 195
 vs. polymyositis (PM), 193
 skin histopathology, 194
 Diffuse idiopathic skeletal hyperostosis (DISH) disease, 60, 61, 458
 Diplopia, 288
 Disc herniation, 455–456, 460
 Discoid lupus erythematosus (DLE), 144, 145
 Disease-modifying antirheumatic drugs (DMARDs), 8, 9, 69, 75
 Distal inter-phalangeal (DIP) joint arthritis, 68
 Dual energy X-ray absorptiometry (DXA), 399
- E**
- Ehlers-Danlos syndrome (EDS)
 bruising, 477
 “cigarette paper” scarring and hemosiderin deposition, 474
 collagen fibril abnormalities, 471
 collagen studies, 475
 EDS-nosology proposal, 472–473
 emotional support, 477–478
 genetic counseling, 475
 hypermobility type of, 475–476
 joint protection, 477
 mitral valve prolapse, 476
 skin care, 477
 skin hyperextensibility, 473
 vascular EDS, 477–478
 Enthesitis, 30, 31, 52, 68–69, 74
 Episcleritis, 255
 Erythema elevatum diutinum (EED)
 photomicrographs, 332
 skin lesions of, 331
 systemic vasculitis, 332
 Esophageal disease, 84
 Etanercept therapy, 18
- F**
- Familial cold autoinflammatory syndrome (FCAS), 41
 Familial Mediterranean fever (FMF), 469
 cardinal clinical findings, 35
 colchicine treatment, 36
 MEFV gene mutation, 34

renal amyloidosis, 36
 renal transplantation, 37
 septic joint, 34
 systemic AA amyloidosis, 37
Fibromyalgia (FM)
 aerobic exercise vs. nonexercise controls, 351
 cognitive behavioral therapy, 351
 diagnosis and etiologies, 349
 disease management, 350
 high glutamate level, 349
 history and physical examination, 347
 impact on National Health Service, 348
 laboratory evaluation, 347
 mood and psychiatric disorders, 345
 outcomes in, 350
 sensory stimuli sensitivity, 350
 and sleep disturbance, 347
 specialist care requirement, 349
 tender point examinations, 346–347
Fibro-osseous dysplasia, 45
Finkelstein's test, 444
Flexor hallucis brevis muscle, 216, 279
Forester's disease. See **Diffuse idiopathic skeletal hyperostosis (DISH) disease**

G

Giant cell arteritis (GCA), 277
 abundant collateral circulation, 303
 diagnosis and imaging
 angiography and ultrasonography, 294
 fluorodeoxyglucose PET (FDG-PET), 295
 fundoscopy, 290
 MRI, 294–295
 pallid disc edema, 290–291
 temporal artery biopsy, 296–298
 laboratory testing, 293–294
 methotrexate (MTX), 305
 pathology
 amyloid deposition, 299
 atherosclerosis, 300
 frozen section analysis, 301
 immunohistochemistry, 300
 necrosis, 299
 transmural inflammation, 299
 and PMR, 304
 symptoms and signs
 abnormal temporal arteries, 287–288
 acute unilateral vision loss, 291
 anterior ischemic optic neuropathy (AION), 289
 audiovestibular dysfunction, 291–292
 diplopia, 288
 facial swelling and noises in head, 291
 fever of unknown origin (FUO), 289
 jaw claudication, 289
 ocular symptoms, 292
 persistent dry cough, 288–289
 unexplained neck pain, 289
 vasculitic neuropathy, 293
 visual hallucinations, 291
 treatment, 302
Gastroesophageal reflux disease (GERD), 84, 85, 171
Glucocorticosteroid therapy, 8
Gottron's papules, 142, 144, 194, 204, 208
Gout
 acute monoarticular arthritis, 355, 357
 epidemiology

coffee consumption, 361
 diabetes associated, 360
 low-fat dairy product consumption, 362
 metabolic syndrome risk, 360
 prevalence and incidence of, 359
 purine-rich foods, 361
 vitamin C intake, 361–362
 joint erosions with overhanging edges, 357
 joint inflammation, 358
 synovial fluid examination, 355, 357
 therapeutic response to colchicines, 355
 tophaceous deposits, 356
 treatment
 allopurinol and azathioprine, 367
 baby aspirin, 370
 colchicine treatment, 365–366
 cyclosporine treatment, 368
 intensive urate-lowering therapy, 369–370
 losartan treatment, 370
 oral glucocorticoids, 365
 renal and heart transplant recipients, 367–368
 serum urate levels, 366–367
 tophi in patients, 368
 uric acid in 24hr collection, 356

H

Hemophagocytic syndrome, 25
Henoch-Schönlein purpura (HSP)
 ankle and dorsum swelling, 226
 gastrointestinal symptoms, 225
 glucocorticoid treatment, 226
 immunofluorescence studies, 228
 immunopathogenesis, 229
 nonsteroidal anti-inflammatory agents (NSAIDs),
 treatment, 226
 palpable purpura, 227
 rash of, 225
 self-limited disorder, 227
 skin biopsy, 225
Hip resurfacing implant, 485
Hormone replacement therapy, osteoporosis, 404
HTLV-I infection, 124
Human leukocyte antigen B27 (HLA) screening test, 51
Hypogammaglobulinemia, 420

I

Idiopathic inflammatory myopathies (IIM)
 azathioprine and methotrexate therapy, 200
 dermatomyositis (DM) vs. polymyositis (PM), 193
 immunosuppressive therapy, 200
 inclusion body myositis (IBM), 200
 MRI, 199–200
 muscle enzymes
 aldolase activity, 196
 creatine kinase (CK) activity, 195
 myositis patients, 196
 serum ALT concentration, 196
 myositis-specific autoantibodies
 anti-SRP antibodies, 198
 skin disease, 193–195
Idiopathic thrombocytopenic purpura (ITP), 164
IgG4-associated systemic disease, 116, 313, 314
IgM rheumatoid factor, 28
Immune-mediated inner ear disease (IMIED)
 auditory and vestibular tests, 392–393

- clinical history, 391
- definition
 - sensorineural hearing loss tinnitus and vertigo, 389
 - sympathetic otitis, 389–390
 - temporal bone and audiovestibular apparatus, 390
- differential diagnosis, 393–395
- treatment, 395
- vestibular nystagmus, 391–392
- Immune thrombocytopenia (ITP), 176
- Inclusion body myositis (IBM), 200
- Inflammatory arthritis, 69, 92, 244, 273, 373
- Inflammatory bowel disease (IBD), 54, 58, 126
- Inflammatory eye disease
 - birdshot retinochoroidopathy, 385
 - CMV vasculitis, 382
 - cotton wool spot diagnosis, 386
 - episcleritis, 382, 385–386
 - glucocorticoids treatment, 382–383
 - infectious uveitis, 383–384
 - intraocular CNS lymphoma, 383
 - ocular tuberculosis, 387
 - orbital pseudotumors, 384
 - pars planitis, 385
 - retinal vasculitis, 381
 - Roth spots, 387
 - scleritis diagnosis, 381–382
 - tubulointerstitial nephritis with uveitis (TINU), 386
- Inflammatory myopathies, 197–198
- J**
- Jaccoud's arthropathy, 3, 117, 136
- Juvenile dermatomyositis (JDM)
 - acanthosis nigricans, 208
 - bone health, 209
 - calcinosis, 206
 - clinical features, 204
 - disease control, 209
 - dystrophic calcifications, 206–207
 - Gottron's papule, 204
 - heliotrope discoloration and erythema, 204
 - IIM differential diagnosis, 205
 - metabolic abnormalities, 207
 - muscle biopsy, 203
 - oral glucocorticoid therapy, 208–209
 - overlap syndrome, 210
 - periungual nailfold capillary change, 206
 - photosensitive rash, 206
 - signs and symptoms, 208
 - sun protection, 209
- Juvenile idiopathic arthritis (JIA), 27–31, 51
- Juvenile rheumatoid arthritis (JRA), 23
- Juvenile spondyloarthropathy
 - enthesitis clinical feature, 52
 - enthesitis-related arthritis (ERA), 51
 - inflammatory bowel disease (IBD), 54
 - inflammatory enthesitis, 53
 - Osgood–Schlatter's disease, 52
 - Patrick/FABER test, 54
 - sacroiliitis, 53
 - tumor necrosis factor (TNF) inhibitors, 55
- K**
- Kawasaki's disease
 - classification criteria, 224
 - conjunctival injection, 222
 - coronary arteries dilation, 223
 - groin area erythema, 224
 - neck swelling symptom, 221
 - and periarteritis nodosa, 224
 - peribronchial infiltrates and mild interstitial infiltrates, 223
 - periodic echocardiograms, 222
 - RSV or PIV test, 222
- Koebner phenomenon, 142
- L**
- Legg-Calve-Perthes disease, 433
- Leukocytoclastic vasculitis, 18, 225, 261, 332, 333
- Leukopenia, 122, 163, 283
- Livedo racemosa, 176, 177, 282, 283
- Livedo reticularis, 176, 177, 227, 282, 283
- Löfgren's syndrome, 417
- Low back and neck pain
 - cervical myelopathy, 462
 - degenerative spondylolisthesis, 457–458
 - disc herniation, 455–456
 - evaluation and treatment, 458–459
 - history and physical examination, 452–454
 - imaging
 - MRI and CT scan, 455
 - red flags, 454
 - important causes, 458
 - mechanical cause, 452, 460
 - spinal stenosis, 456–457
 - spine basic anatomy, 451
 - surgery, 459–460
 - whiplash injury, 461
- Lupus anticoagulant (LA) phenomenon, 174
- Lupus pernio, 416
- Lupus psychosis, 147
- Lyme disease, 103
- M**
- Macrophage activation syndrome (MAS), 28, 163
- MALT lymphoma, 116, 123, 125
- Membranoproliferative glomerulonephritis (MPGN), 273
- Meniere's disease, 394
- Metacarpophalangeal (MCP) joints, 3, 80, 82, 425
- Mevalonic aciduria, 39
- Microscopic polyangiitis (MPA), 283
 - alveolar hemorrhage, 256–257
 - clinical phenotypes, 256
 - interstitial fibrosis, 255
 - pulmonary hemorrhage, 256
 - RBC with glomerulonephritis, 259
 - treatment and course, 264–267
 - vasculitic neuropathy, 262
- Mikulicz disease, 124–125
- Mixed connective tissue disease (MCTD)
 - anti-RNP antibody emergence, 170
 - diffuse swelling, fingers, 171
 - gastroesophageal reflux, 171
 - myositis, 171
 - nasal septal perforation, 172
 - sclerodactyly and digital ischemia, 171
 - sicca symptoms and pulmonary hypertension, 170
 - unilateral or bilateral trigeminal neuropathy, 169
- Monogenic autoinflammatory syndromes
 - cherubism, 45–46
 - chronic recurrent multifocal osteomyelitis (CRMO)
 - congenital dyserythropoietic anemia (CDA), 43
 - primary intraosseous lymphoma, 44
 - cryopyrin-associated periodic syndromes (CAPS)

- bony deformities, 42
 - CIAS1 mutation, 41
 - cochlear inflammation, 42
 - familial Mediterranean fever (FMF)
 - cardinal clinical findings, 35
 - colchicine treatment, 36
 - MEFV gene mutation, 34
 - renal amyloidosis, 36
 - renal transplantation, 37
 - septic joint, 34
 - systemic AA amyloidosis, 37
 - hereditary periodic fever syndromes, 33
 - hyper immunoglobulin D and periodic fever syndrome
 - hyper IgD syndrome (HIDS), 39
 - prognosis, 40
 - splenomegaly and gastrointestinal manifestations, 39
 - PAPA syndrome, 44–45
 - tumor necrosis factor receptor-associated periodic syndrome (TRAPS)
 - anti-IL-1 treatment, 38
 - TNFRFS1A mutations, 39
 - Muckle-Wells syndrome (MWS), 23, 41
 - Multicentric reticulohistiocytosis, 5
 - Muscle atrophy, 30, 205, 440
 - Musculoskeleton complaints
 - ankle, 448–449
 - coccyx, 445
 - elbow pain
 - antecubital area swelling, 443
 - septic olecranon bursitis, 442
 - hand, 444–445
 - hip, 445–446
 - knee
 - anserine bursa, 448
 - aspiration to, 447
 - best injecting way, 446
 - leg cramps, 445
 - shoulder pain
 - brachial plexopathy, 440
 - humeral head superior migration, 440
 - microcrystalline disease, 441
 - palpable effusion, 442
 - posterolateral approach, injections, 441
 - subacromial bursa injections, 440
 - wrist
 - carpal tunnel syndrome (CTS), 443
 - Finkelstein's test, 444
 - Mycophenolate mofetil (MMF), 152, 155, 186, 367
 - Myocardial infarction, 16, 134, 151
- N**
- Neisseria gonorrhoea, 76
 - Neonatal lupus erythematosus (NLE), 162
 - Neonatal onset multisystem inflammatory disorder (NOMID) syndrome, 41, 42
 - Nephrocalcinosis, 119
 - Nephrogenic systemic fibrosis (NSF) and scleroderma mimickers
 - clinicopathological diagnosis, 99
 - dermal tissue injury, 102
 - Doppler techniques, 101
 - eosinophilic fasciitis, 105
 - fibrosing disorders, 98
 - gadolinium-based contrast agent, 100
 - hemodialysis, 103
 - histopathological findings, 99
 - kidney dysfunction, 100
 - localized scleroderma, 103
 - morphea, 103–104
 - nephrogenic fibrosing dermopathy (NFD), 97
 - risk factor, 100
 - scleromyxedema, 104–105
 - therapeutic agents, 102
 - yellow scleral plaques, 101, 102
 - Neutropenia, 122
 - Nonsteroid antiinflammatory drugs (NSAIDs), 53, 61
- O**
- Oral glucocorticoid therapy, 208–209
 - Osteoarthritis (OA)
 - aging outcome, 425
 - articular cartilage damage, 426
 - carpometacarpal joint, 433
 - dimethylsulfoxide treatment, 427
 - glucocorticoid injections, 429
 - groin pain, 431–432
 - joint degeneration
 - course, 428
 - initial stages, 430–431
 - joint pain, 426
 - knuckle cracking, 425
 - Legg-Calve-Perthes disease, 433
 - leg length discrepancy, 428
 - mild hip dysplasia, 431, 432
 - MRI, 428
 - patellofemoral OA, 431
 - radiographs assessment, 429, 430
 - recreational running risk, 425
 - risk factors, 428
 - slipped capital epiphysis, 432
 - viscosupplementation efficacy, 433
 - Osteonecrosis
 - antero-posterior radiograph, stage IV, 485
 - arthroplasty treatment, 485
 - bone marrow edema syndrome, 483
 - early stages, 481–482
 - femoral head
 - blood supply disruption, 482
 - core decompression, 484
 - hip resurfacing, for collapse of, 485
 - hip MRI, 482–483
 - plain radiograph, 482
 - risk factors, 481
 - secondary osteonecrosis
 - vs. spontaneous, 486
 - treatment algorithm, 483
 - Osteonecrosis of the jaw (ONJ), 404–405
 - Osteoporosis
 - diagnosis, bone mass measurement
 - DXA scans, 399
 - fracture risks, 399
 - low bone density, 399–400
 - epidemiology
 - among African Americans, 397
 - among men, 398
 - hereditary disorder of collagen, 398
 - low trauma fractures, 398–399
 - prevention
 - calcium and sodium effects, 400–402
 - vitamin D, 402–403
 - treatment
 - bisphosphonates, 404–405
 - general considerations, 403–404

- hormone replacement therapy, 404
 - treatment WHO definition, 397
- P**
- Paget's disease of bone
 - asymptomatic disorder, 409
 - etidronate and teraparotide treatment, 411
 - monostotic and polyostotic disorder, 410
 - radiographic findings, 411
 - Parainfluenza virus (PIV) test, 222
 - Pars planitis, 384, 385, 419
 - Pauciarticular JIA, 29, 31
 - Pauci-immune glomerulonephritis, 20
 - Pediatric systemic lupus erythematosus
 - autoimmune lymphoproliferative syndrome (ALPS), 164–165
 - cerebral vein thrombosis, 161
 - cutaneous neonatal lupus, 162, 163
 - discoid lesions, 165
 - glucocorticoids dose, 161
 - herpes virus infection, 163
 - MAS and macrocephaly, 163
 - neonatal lupus erythematosus (NLE), 162
 - proliferative lupus nephritis, 164
 - telangiectasias, 165
 - Pediatric vasculitis
 - classification scheme, 231
 - Henoch-Schönlein purpura (HSP)
 - gastrointestinal symptoms, 225
 - glucocorticoid treatment, 226
 - immunofluorescence studies, 228
 - immunopathogenesis, 229
 - nonsteroidal anti-inflammatory agents (NSAIDs), treatment, 226
 - palpable purpura, 227
 - rash of, 225
 - self-limited disorder, 227
 - skin biopsy, 225
 - Kawasaki's disease, 221–224
 - polyarteritis nodosa (PAN), 229–231
 - von Willebrand factor antigen, 231
 - Peritoneal dialysis, 103
 - Plantar fasciitis, 448, 449
 - Pneumocystis carinii (jiroveci) pneumonia (PCP), 150
 - Polyarteritis nodosa (PAN)
 - ACR classification criteria, 229
 - antinuclear antibody (ANA), 277
 - atrophie blanche, 285
 - cutaneous PAN, 230
 - diabetes mellitus, 278
 - diagnosis, 279
 - hepatitis B-related PAN, 229
 - leg ulcers diagnosis, 281
 - livedoid vasculopathy, 285
 - livedo racemosa, 283
 - livedo reticularis, 282
 - magnetic resonance angiography, 284
 - microaneurysm, 283, 284
 - nodular vasculitis, 282
 - peripheral nervous system vasculitis, 278
 - renal vasculature, 284
 - skin biopsy, 285
 - skin ulcer diagnosis, 282
 - thrombocytopenia, 283
 - vasculitic neuropathy, 278, 279
 - visceral abdominal angiography, 284
 - Polymyalgia rheumatica (PMR)
 - and GCA, 304
 - prednisone treatment, 302, 304
 - vs. RA, 304
 - shoulder pain symptom, 288
 - Polymyositis (PM)
 - vs. dermatomyositis (DM), 193
 - vs. IBM, 199–200
 - immunosuppressive therapy, 200
 - Posterior reversible encephalopathy syndrome (PRES), 147
 - Prednisone monotherapy, 313
 - Pregnancy, rheumatic disease
 - antiphospholipid syndrome (APS), 189
 - breastfeeding, 187
 - dyspnea, 184
 - elevated erythrocyte sedimentation rate (ESR), 184
 - infertility, 183
 - medications
 - hydroxychloroquine, 186
 - ibuprofen, 187
 - methotrexate or leflunomide, 186
 - mycophenolate mofetil (MMF) and azathioprine, 186
 - steroid, 185
 - sulfasalazine, 187
 - neonatal lupus syndromes, 189–190
 - ovarian stimulation, 184
 - proteinuria and creatinine level, 184
 - rheumatoid arthritis, 190
 - systemic lupus erythematosus (SLE)
 - lupus flare and preeclampsia, 188
 - oral contraceptives, 187
 - renal allografts, 188
 - thrombocytopenia, 188
 - Primary angiitis of the CNS (PACNS)
 - brain imaging, 316
 - lumbar puncture, diagnosis, 315
 - with mass lesion, 315
 - vs. RCVS
 - angiographic features, 317
 - blood and CSF test results, 319
 - clinical features, 317
 - cross-sectional neuroimaging, 317–318
 - Primary biliary cirrhosis (PBC) symptom, 83
 - Proliferative lupus nephritis, 164
 - Psoriatic arthritis (PsA), 29
 - coronary artery disease, 70
 - cutaneous psoriasis, 69
 - dactylitis, 68
 - inflammatory arthritis, 69
 - vs. RA, 68
 - rheumatoid arthritis (RA), 67
 - skin and joint disease, 70
 - Pulmonary arterial hypertension (PAH), 77, 88–90
 - Pulmonary fibrosis, 86
- R**
- Raynaud's phenomenon (RP), 117, 123, 172, 324
 - acro-osteolysis, 79
 - antinuclear antibody assay (ANA), 77
 - calcium channel blockers, 78
 - cyanosis ischemia correlation, 79
 - dilated capillary loops, 78
 - skin induration, 77
 - vasodilator therapy, 79
 - Reactive arthritis (ReA)
 - circinate balanitis, 76
 - dactylitis pattern, 73

- diagnostic test, 74
- disease-modifying antirheumatic drugs (DMARDs), 75
- enthesitis, 74
- gastrointestinal infections, 75
- gonococcal arthritis, 76
- monoarthritis, 73
- psoriatic arthritis, 76
- rheumatic fever, 74
- rheumatoid arthritis, 75
- septic arthritis, 73
- synovial fluid, 74
- Relapsing polychondritis (RP)
 - cartilaginous part inflammation, 339
 - chest radiograph, 341
 - direct laryngoscopy, 342
 - irreversible hearing loss, 339
 - nose bridge collapse, 341
 - patient with tracheostomy, 342
 - pinna involvement, 340
 - recurrent pneumonias or bronchiectasis, 342
 - respiratory symptoms, 340
 - subglottic stenosis tomogram, 341
 - vertigo and hearing difficulties, 339
- Renal dysfunction, 274
- Respiratory syncytial virus (RSV) test, 222
- Reversible cerebral vasoconstriction syndromes (RCVS)
 - bad migraine attack, 319
 - brain imaging, 318
 - key diagnosis elements, 317
 - vs. PACNS
 - angiographic features, 317
 - blood and CSF test results, 319
 - clinical features, 317
 - cross-sectional neuroimaging, 317–318
 - pharmacological blood pressure observation, 320
 - transcranial Doppler studies, 319
 - vasoconstrictive medications avoidance, 320
- Rheumatoid arthritis (RA), 107
 - adverse effects
 - cardiovascular disease, 11
 - hepatitis B virus infection, 10
 - clinical features
 - amyloidosis, 3
 - synovitis and radiographic progression, 2
 - diagnosis, 1
 - disease assessment
 - patient global assessment (PGA), 7
 - simplified disease activity index, 6
 - immunizations, 11
 - mimickers
 - calcium pyrophosphate dehydrate (CPPD) deposition disease, 3, 4
 - chronic tophaceous gout, 3
 - erosive osteoarthritis, 5
 - parvovirus infection, 4
 - symmetrical polyarthritis, 3
 - serological features and radiology, 5–6
 - serum rheumatoid factor, 6
 - treatment
 - antibacterial effects, 9
 - biologic DMARDs, 7
 - cholestyramine, 8
 - human antichimeric antibodies [HACA], 10
 - methotrexate (MTX) therapy, 8, 9
 - tumor necrosis, 9
- Rheumatoid nodules, 2
- Rheumatoid vasculitis
 - anti-TNF therapy, 17
 - corneal melt syndrome, 20
 - cyclophosphamide, 15
 - glomerular pathology, 21
 - leg ulcers, 17
 - mononeuritis multiplex symptom, 18
 - myocardial infarction, 16
 - pulmonary rheumatoid nodules, 20
 - pyoderma gangrenosum, 17
 - rheumatoid factor, 21
 - symmetric polyneuropathy, 18
 - vasculitic neuropathy diagnosis, 19
- Rodnan skin score method, 84
- Roth spots, 387
- S**
- SAPHO syndrome, 44
- Sarcoidosis
 - BAL, CD4:CD8, 415
 - Bell's palsy, 414
 - bilateral hilar adenopathy, 414–415
 - in black patients, 413
 - clinical outcomes, 414, 422
 - ECG monitoring, 419
 - erythema nodosum, leg, 417
 - Fatigue Assessment Scale (FAS), 418
 - granulomatous disease, 420
 - high resolution CT scan, 415
 - liver involvement, 418
 - Löfgren's syndrome, 417
 - lupus pernio, 416
 - pars planitis and optic neuritis, 419
 - peribronchial thickening, 416
 - predictive features, 417
 - prevalence of, 414
 - pulmonary hypertension incidence, 422
 - pulmonary sarcoidosis, 420–421
 - traction bronchiectasis, 416
- Seronegative spondyloarthropathies, 67, 69, 452
- Seropositive rheumatoid arthritis, 78
- Serum monoclonal gammopathy, 124
- Sjögren's syndrome (SjS), 81, 162
 - classification and epidemiology
 - American–European classification criteria, 108
 - Klinefelter syndrome, 108–109
 - patient classification/diagnosis, 107
 - differential diagnosis, 124–125
 - extraglandular involvement
 - Devic's disease, 120
 - dyspareunia, 122
 - dysphagia, 116
 - erosive symmetrical arthritis, 117
 - glomerulonephritis, 119
 - Hepatitis C virus (HCV) infection, 118
 - interstitial fibrosis, 117
 - lacrimal/parotid glands, 121
 - liver function tests, 118
 - lymphocytic vasculitis, 116
 - pancreatic cancer, 119
 - peripheral neuropathies, 119–120
 - sensorineural hearing loss, 121
 - sensory neuropathy, 120
 - thyroid disease, 122
 - trigeminal neuralgia, 120
 - immunological assays

- hematological neoplasm, 124
 - Raynaud's phenomenon, 123
 - keratoconjunctivitis sicca, 107
 - laboratory findings, 122–123
 - parotid and submandibular involvement, 115–116
 - pathogenesis, 109
 - prognosis, 125–126
 - sicca Features
 - ocular manifestations, 109–111
 - oral manifestations, 111–115
 - systemic treatment, 126
 - SLE disease activity index (SLEDAI), 146
 - Spinal stenosis, 456–457
 - Spondylolisthesis, 457–458
 - Subacute cutaneous lupus erythematosus (SCLE), 138, 144
 - Sydenham's chorea, 161
 - Synovial enthesal complex (SEC), 69
 - Systemic lupus erythematosus (SLE)
 - arthritis of, 163
 - autoimmune lymph proliferative syndrome (ALPS), 164
 - central nervous system lupus
 - neuropsychiatric lupus, 146
 - optic neuritis, 147
 - cerebral vein thrombosis, 161
 - clinical features
 - autoimmune hemolytic anemia (AIHA), 136
 - autoimmune liver disease, 134
 - autoimmune vs. lupus-associated hepatitis, 135
 - cardiovascular disease, 133
 - idiopathic inflammatory myopathies, 136
 - primary biliary cirrhosis, 135
 - cutaneous lupus
 - alopecia areata, 140
 - clinical effects, 138
 - discoid lupus lesions, 144
 - epidermolysis bullosa acquisita, 139
 - eruptive dermatofibromas, 141
 - koebnerize, 142
 - lupus panniculitis, 140
 - malar rash, 136
 - mycobacterial infections, 141
 - nasolabial folds, 137
 - oral ulcerations, 142
 - vermillion border, 143
 - vitamin D levels, 145
 - diagnosis
 - American College of Rheumatology (ACR), 131, 132
 - autoimmune thyroiditis, 132
 - skin biopsy, 133
 - diffuse central nervous system dysfunction, 164
 - diffuse/focal myocarditis, 151
 - discoid lesions, 165
 - erythrocyte sedimentation rate (ESR), 148
 - idiopathic thrombocytopenic purpura (ITP), 164
 - lupus nephritis
 - glomerulonephritis, 146
 - renal dysfunction, 145–146
 - serum creatinine, 145
 - partial thromboplastin time (PTT), 161
 - pregnancy
 - lupus flare and preeclampsia, 188
 - oral contraceptives, 187
 - renal allografts, 188
 - thrombocytopenia, 188
 - proliferative lupus nephritis, 164
 - treatment
 - antimalarial therapy, 152
 - azathioprine, 155
 - chloroquine treatment, 153
 - immunosuppressive drug regimens, 152
 - osteonecrosis, 154
 - quinacrine therapy, 153
 - renal disease, 153–154
 - Varicella zoster immunization, 150
 - Systemic-onset juvenile idiopathic arthritis (sJIA)
 - antiCCP antibodies, 28
 - knee monoarthritis, 30
 - leukemic arthritis, 31
 - oligoarticular JIA, 29
 - pauciarticular JIA, 31
 - sacroiliitis, 30
 - thrombocytosis, 31
 - Systemic rheumatic diseases, 133
 - Systemic sclerosis (scleroderma)
 - antibodies and disease phenotypes
 - anti-centromere antibodies, 80
 - epidemiologic risk factor, 82
 - the health assessment questionnaire disability index (HAQ-DI), 82
 - pulmonary fibrosis, 83
 - RNA polymerase, 81
 - cardiac disease, 90
 - diagnosis, 80
 - gastrointestinal involvement
 - gastric antral vascular ectasia, 84
 - proton pump inhibitors (PPIs), 85
 - xerostomia, 84
 - interstitial lung disease (ILD)
 - bronchoalveolar lavage (BAL), 86
 - cyclophosphamide therapy, 87
 - forced vital capacity (FVC), 85
 - glucocorticoids, 86
 - velcro crackles, 88
 - Wegener's granulomatosis etanercept trial (WGET), 88
 - musculoskeletal manifestations, 91–92
 - peripheral neuropathy, 92
 - pulmonary arterial hypertension (PAH)
 - echocardiography, 88
 - parenchymal lung disease, 89
 - pulmonary artery pressure, 90
 - Raynaud's phenomenon (RP) and digital ischemia
 - acro-osteolysis, 79
 - antinuclear antibody assay (ANA), 77
 - calcium channel blockers, 78
 - cyanosis ischemia correlation, 79
 - dilated capillary loops, 78
 - skin induration, 77
 - vasodilator therapy, 79
 - scleroderma renal crisis
 - ACE inhibitor, 90
 - angiotensin II inhibitors, 91
 - skin disease
 - pterygium inversum unguis condition, 83
 - scleroderma, 84
 - telangiectasias, 83
- T**
- Takayasu's arteritis (TA)
 - abnormal angiogram, 312
 - cardiomyopathy differential diagnosis, 310

- carotid bypass grafts, CNS symptoms, 313
 - contraindicated pregnancy, 314
 - ESR and CRP gauges, 312
 - femoral artery involvement, 310
 - fibromuscular dysplasia, 311
 - vs. GCA, 311
 - IgG4-related systemic disease, 313, 314
 - markedly abnormal acute phase response, 312
 - monophasic illness, 310
 - prednisone monotherapy, 313
 - Temporal artery biopsy, GCA
 - contraindications to, 296
 - frozen section analysis, 301
 - GCA diagnosis, 296
 - immunohistochemistry aid, 300
 - likelihood estimation ratio, 288
 - longitudinal section of, 299
 - optimal and risky sites, 298
 - in scalp, 298
 - Tendinitis, 439
 - Thromboangiitis obliterans
 - amputation risk, 321
 - clinical and angiographic findings, 322, 326
 - early lesions in, 322
 - extra-extremity disease, 325
 - necrotic fingertips amputation, 325–327
 - nicotine addiction, 321
 - Raynaud's phenomenon, 324
 - splinter hemorrhages, 325
 - superficial thrombophlebitis manifestation, 323–324
 - systemic vasculitis, 322
 - young men disease, 323
 - Tubulointerstitial disease, 119
 - Tubulointerstitial nephritis with uveitis (TINU), 386
- U**
- Undifferentiated connective tissue disease (UCTD), 169. See also
 - Mixed connective tissue disease (MCTD)
 - U3RNP autoantibodies, 80
 - Urticarial vasculitis
 - hypocomplementemic vasculitis
 - low complement C1q level, 335
 - vs. normocomplementemic, 333
 - palpable purpura, 336
 - scleritis, 337
 - lesions of 3 day's duration, 335
 - prednisone treatment, 334
 - skin biopsy, 334
 - Uveitis-band keratopathy, 29
- V**
- Vasculitic neuropathy
 - cyclophosphamide and glucocorticoids
 - treatment, 219–220
 - diagnosis, 19
 - electrodiagnosis and biopsy
 - bilateral nerve conduction studies, 216
 - flexor hallucis brevis muscle examination, 216–217
 - muscle biopsy, 217–218
 - multiple mononeuropathies, 216
 - neurological pattern, 213
 - neurophysiologic patterns, 217
 - pain and paresthesias, 215
 - pathophysiology
 - nerve fiber pathology, 218
 - neural vasculature, 218
 - perivascular inflammatory infiltrates, 218–219
 - vascular histopathology diagnosis, 219
 - polyneuropathy
 - manifestations, 213
 - onset and progression, 214
 - sensory deficits, 214
 - systemic and nonsystemic vasculitis, 215
 - Vestibular nystagmus, 391–392
- W**
- Wegener's granulomatosis (WG), 10
 - bladder, 261
 - clinical features, 248
 - clinical phenotypes, 256
 - CNS, 262–263
 - consensus classification criteria, 230
 - eye
 - episcleritis, 255
 - orbital pseudotumor, 254
 - tarsal structure in, 254
 - kidneys
 - granulomas in renal biopsy, 258
 - prednisone treatment, 260
 - prognostication, 260
 - lungs
 - chest radiography, 257
 - normal saline nebulizer treatment, 257
 - venous thrombotic events (VTE), 255–256
 - misdiagnosis, 250
 - mouth
 - roof erosion, 254
 - strawberry gums, 253
 - tongue ulcer, 253
 - nasal crusting, 249
 - peripheral seventh cranial nerve palsy, 262
 - splenic involvement, 263
 - subglottic stenosis, 229
 - diagnosis over phone, 251
 - dyspnea on exertion, 250
 - flow volume loops, 252
 - metal tracheal stents avoidance, 251
 - treatment and course, 264–267
 - wrist arthritis, 262
 - Whiplash injury, 461